<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>subcutaneous injection systems &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/subcutaneous-injection-systems/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 20 Aug 2025 19:29:01 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>subcutaneous injection systems &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>New Drug Formulation Transforms Intravenous Treatments into Rapid Injections</title>
		<link>https://bioengineer.org/new-drug-formulation-transforms-intravenous-treatments-into-rapid-injections/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 20 Aug 2025 19:29:01 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[drug delivery innovation]]></category>
		<category><![CDATA[polymer excipient technology]]></category>
		<category><![CDATA[protein therapeutic stability]]></category>
		<category><![CDATA[subcutaneous injection systems]]></category>
		<category><![CDATA[ultra-high concentration biologics]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-drug-formulation-transforms-intravenous-treatments-into-rapid-injections/</guid>

					<description><![CDATA[In the realm of modern medicine, the administration of protein-based therapeutics has long presented a formidable challenge. Patients battling cancers, autoimmune diseases, and various metabolic disorders frequently undergo prolonged intravenous (IV) infusions, a method required primarily due to the stability constraints of protein drugs. These biomolecules often must be formulated at low concentrations to maintain [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">256585</post-id>	</item>
	</channel>
</rss>
